NuPathe Inc. Appoints William J. Federici to Its Board of Directors

CONSHOHOCKEN, PA--(Marketwire - January 05, 2011) - NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announced that William J. Federici, vice president and chief financial officer of West Pharmaceutical Services, Inc., has been appointed to the NuPathe Board of Directors. Mr. Federici will also serve on the Audit Committee.

“We are delighted to add Bill to our Board of Directors,” said Jane Hollingsworth, chief executive officer of NuPathe. “In addition to his significant financial and accounting acumen, Bill’s experience as a chief financial officer of a global manufacturer of components and delivery systems for the pharmaceuticals, healthcare and consumer products industries will be invaluable to the company, especially as we prepare for a robust commercial launch of Zelrix.”

Mr. Federici joined West Pharmaceutical Services in 2003 with more than 20 years’ experience in public accounting for the pharmaceutical industry. Prior to joining West, Mr. Federici served as practice leader for the pharmaceuticals industry in the Americas and engagement partner for several pharmaceutical companies at KPMG LLP.

Mr. Federici holds a BA in Economics and an MBA in Professional Accounting from Rutgers University and is a Certified Public Accountant. Mr. Federici is also an Advisory Board Member of the Rutgers University School of Business, and a member of the Board of Trustees at Cancer Care of New Jersey.

About NuPathe

NuPathe Inc. (www.nupathe.com) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe’s most advanced product candidate, Zelrix, is a single-use, transdermal sumatriptan patch being developed for the treatment of acute migraine. In addition to Zelrix, NuPathe has two proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson’s disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.